Supplemental material for Risueño et al. manuscript titled "Molecular features associated with response to enasidenib plus azacitidine in newly diagnosed *IDH2*-mutated AML"

Supplemental Table 1. Gene mutations observed in ≥ 20% of patients at study entry.

Mutated gene	Frequency, n (%)
IDH2	86 (100)
ASXL1	46 (53)
SRSF2	43 (50)
DNMT3A	42 (49)
CEBPA	32 (37)
TET2	32 (37)
BCOR	29 (34)
RUNX1	28 (33)
FLT3	25 (29)
STAG2	25 (29)
GATA1	23 (27)
SF3B1	21 (24)
DDX41	20 (23)
KIT	18 (21)